Join
Live feed
·
PRReleasevia Quantisnow
Fulcrum Therapeutics Inc. logo

Fulcrum Therapeutics Announces Positive Interim Results from Phase 1 Healthy Adult Volunteer Trial of FTX-6058 for Sickle Cell Disease

ByQuantisnow·Wall Street's wire, on your screen.
FULC· Fulcrum Therapeutics Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track FULC (Fulcrum Therapeutics Inc.) and more on Quantisnow.